对VITEK2-Compact肺炎链球菌GP68药敏卡的性能评估

摘要

Objective To evaluate the performance of GP68 Antibiotic Susceptibility Testing card in testing the susceptibility of Streptococcus pneumoniae on VITEK 2-Compact system,taking E-test as reference.Methods A total of 98 strains of S.pneumoniae were collected and subjected to susceptibility testing using E-test and VITEK 2-Compact (AST-GP68) in Luzhou People's Hospital form January 1 to December 31,2015.Results According to the breakpoints of Clinical and Laboratory Standards Institute (CLSI),category agreement (CA) of penicillin was 80.6％.Very major error (VME) was 0.Major error (ME) was 12.2％,minor error (mE) was 7.1％.CA of ceffriaxone was 90.8％,VME 0,ME 4.1％,mE 5.1％.CA of cefotaxime was 91.8％,VME 0,mE 5.1％,mE 3.1％.CA of meropenem was 85.7％,VME 0,ME 2.0％,mE 12.2％.CA of other antibiotics (amoxicillin,ertapenem,erythromycin,tetracycline,chloramphenicol,telithromycin,linezolid,vancomycin,moxifloxacin,ofloxacin,levofloxacin) was 100％.Conclusions AST-GP68 on VITEK 2-Compact system may have false results of antimicrobial resistance to some antibiotics such as penicillin,ceftriaxone,cefepime,meropenem due to the defects of the underlying principle.Such false results should be verified by other methods in clinical practice.%目的 评估VITEK 2-Compact肺炎链球菌GP68药敏卡的性能,以E试验为参比方法.方法 收集2015年1-12月98株肺炎链球菌,采用VITEK 2-Compact AST-GP68药敏卡进行药敏测定,结果与E试验结果进行对照.结果 按CLSI标准,98株肺炎链球菌中青霉素的分类符合率(CA)为80.6％、严重错误(VME)为0、重大错误(ME)为12.2％、微小错误(mE)为7.1％;头孢曲松CA为90.8％、VME为0、ME为4.1％、mE为5.1％;头孢噻肟CA为91.8％、VME为0、ME为5.1％、mE为3.1％;美罗培南CA为85.7％、VME为0、ME为2.0％、mE为12.2％;阿莫西林、厄他培南、红霉素、四环素、氯霉素、泰利霉素、利奈唑胺、万古霉素、喹诺酮类(莫西沙星、氧氟沙星、左氧氟沙星)、甲氧苄啶-磺胺甲(哑)唑CA为100％.结论 VITEK 2-Compact AST-GP68由于检测原理缺陷使其对某些抗菌药物如青霉素、头孢曲松、头孢噻圬、美罗培南等的药敏试验结果出现假耐药现象,临床在遇到此类现象时,需采用其他方法进行复核确认.